Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015-2019

Published: June 2015

Global Anti-Bacterial Drugs Market

Assessment & Forecast:

2015-2019

Segments Assessed: (Cubicin, Teflaro/Zinforo, Dificid, Dalvance,

Orbactiv, Sivextro, Zerbaxa, Avycaz, Zyvox, Avelox, Augmentin,

Zosyn/Tazocin, Invanz, Tygacil, Surotomycin, Solithromycin, Delafloxacin,

Plazomycin, Taksta, Cadazolid, Carbavance, Eravacycline and Others).

Geographies Assessed: North America, Europe, Asia-Pacific, Latin

America, Middle-East and Africa.

Global Anti-Bacterial Drugs Market Assessment, Forecast (2015-2019)

2

About Us

Spearhead Acuity Business Research & Consulting (SA-BRC) is a premium Life Science business

intelligence and data analytics firm. The SA-BRC team offers a wide range of business intelligence

services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals,

Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the

entire value chain of healthcare industry. Our research and consulting capabilities extend across

several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical

Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Our skills and capabilities help put forth the most accurate perspective of the market. We track all

major and minor events that create ripples and affect the life-science market in numerous ways. Our

data modeling process includes the evaluation of impacting events and analyzing other invaluable

sources (public & proprietary) of information and finally reporting results that will influence the

decision making of the readers.

SA-BRC has helped start-ups and market leaders across the globe achieve their revenue goals

strategically in multiple stages such as adoption, pre-launch research, regional analysis, social media

analytics, competitive mapping, market entry and post marketing surveillance. We frequently build

panels of experts for gathering data and invite participants of the healthcare industry to share their

opinions and views on our reports. Our current network of industry experts spans across all major

life-science domains and take pride in keeping ourselves abreast with the latest happenings within

the sphere of Life-Science.

Report:

GLOBAL NON-VASCULAR

STENTS MARKET

2013-2019


3

Table of Content

Chapter 1 Preface 9

1.1 Research Scope 9

1.1.1 Market Segmentation 10

1.1.2 Postulations 11

1.2 Methodology of Research 12

1.2.1 Companies covered in this report 13

Chapter 2 Précis 14

2.1 Market Inferences 14

Chapter 3 Market Dynamics 16

3.1 Market Drivers 16

3.1.1 Increasing incidence of hospital and community acquired bacterial infections pushing

growth of brands and generics 16

3.1.2 Improving Legal Framework for provision of Incentives expected to drive growth 16

3.2 Market Inhibitors 16

3.2.1 Limited pipeline drugs and absence of new indication targets may lead to significant erosion against generics 16

3.3 Opportunities 17

3.3.1 R&D in treatment of carbapenem-resistant enterobacteria will open new market 17

3.3.2 Existence of Considerable Target Population in Emerging Economies 17

Chapter 4 Global Anti-Bacterial Drugs Market Assessment, by Current

Marketed Brands - Size & Forecast, 2015 – 2019 (US$

Millions) 18

4.1 Introduction 18

4.2 Cubicin (daptomycin) Market, US$ Mn (2013 - 2019) 18

4.3 Teflaro/Zinforo (ceftaroline) Market, US$ Mn (2013 - 2019) 19

4.4 Dificid (fidaxomicin) Market, US$ Mn (2013 - 2019) 20

4.5 Dalvance (dalbavancin) Market, US$ Mn (2013 - 2019) 21

4.6 Orbactiv (oritavancin) Market, US$ Mn (2013 - 2019) 22

4.7 Sivextro (tedizolid) Market, US$ Mn (2013 - 2019) 23

4.8 Zerbaxa (ceftolozane + tazobactam) Market, US$ Mn (2013 - 2019) 24

4.9 Avycaz (ceftazidime-avibactam) Market, US$ Mn (2013 - 2019) 25

4.10 Zyvox (linezolid) Market, US$ Mn (2013 - 2019) 26

4.11 Avelox (moxifloxacin) Market, US$ Mn (2013 - 2019) 27

4.12 Augmentin (amoxicillin + clavulanic acid) Market, US$ Mn (2013 - 2019) 28


4

4.13 Zosyn/Tazocin (piperacillin + tazobactam) Market, US$ Mn (2013 - 2019) 29

4.14 Invanz (ertapenem) Market, US$ Mn (2013 - 2019) 30

4.15 Tygacil (tigecyline) Market, US$ Mn (2013 - 2019) 31

4.16 Other Prominent Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019) 32

Chapter 5 Global Anti-Bacterial Drugs Market Assessment for Pipeline

Drugs - Size & Forecast, 2015 – 2019 (US$ Millions) 33

5.1 Introduction 33

5.2 Surotomycin Market, US$ Mn (2013 - 2019) 33

5.3 Solitaire (solithromycin) Market, US$ Mn (2013 - 2019) 34

5.4 Delafloxacin Market, US$ Mn (2013 - 2019) 35

5.5 Plazomycin Market, US$ Mn (2013 - 2019) 35

5.6 Taksta (fusidic acid) Market, US$ Mn (2013 - 2019) 36

5.7 Cadazolid Market, US$ Mn (2013 - 2019) 37

5.8 Carbavance Market, US$ Mn (2013 - 2019) 38

5.9 Eravacycline Market, US$ Mn (2013 - 2019) 39

5.10 Other Early-Stage Anti-Bacterial Candidates 40

5.10.1 Finafloxacin 40

5.10.2 Omadacycline 40

5.10.3 Zabofloxacin 40

5.10.4 Ramoplanin 40

5.10.5 Nemonoxacin 41

5.10.6 Relebactam (MK-7655) 41

Chapter 6 Global Anti-Bacterial Drugs Market Assessment –Size &

Forecast, By Geography, 2015 – 2019 (US$ Millions) 42

6.1 Introduction 42

6.2 North America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019) 43

6.3 Europe Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019) 44

6.4 Asia-Pacific Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019) 45

6.5 Latin America Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019) 46

6.6 Middle-East Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019) 47

6.7 Africa Anti-Bacterial Drugs Market, US$ Mn (2013 - 2019) 48

Chapter 7 Key Players Analysis: Global Anti-Bacterial Drugs Market,

2014 (%) 50

7.1 Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%) 50

7.2 Global Anti-Bacterial Drugs Market: Recent Developments 2013-2015 51


5

7.2.1 Mergers and Acquisitions 51

7.2.2 New Product Launches and Approvals 51

7.3 Competitive Landscape: Strategies 53

Chapter 8 Epilogue 54


6

List of Figures

FIG. 1 Market Segmentation: Anti-Bacterial Drugs Market Assessment & Forecast (2015-2019) 10

FIG. 2 Research Methodology: Global Anti-Bacterial Drugs Market Assessment 12

FIG. 3 Global Anti-Bacterial Drugs Market Share, by Geography 2014 & 2019 (% Share - US$ Million) 15

FIG. 4 Global Anti-Bacterial Drugs Market – Cubicin (daptomycin) Revenues 2013 – 2019 (US$ Millions) 19

FIG. 5 Global Anti-Bacterial Drugs Market – Teflaro/Zinforo (ceftaroline) Revenues 2013 – 2019 (US$ Millions) 20

FIG. 6 Global Anti-Bacterial Drugs Market – Dificid (fidaxomicin) Revenues 2013 – 2019 (US$ Millions) 21

FIG. 7 Global Anti-Bacterial Drugs Market – Dalvance (dalbavancin) Revenues 2013 – 2019 (US$ Millions) 22

FIG. 8 Global Anti-Bacterial Drugs Market – Orbactiv (oritavancin) Revenues 2013 – 2019 (US$ Millions) 23

FIG. 9 Global Anti-Bacterial Drugs Market – Sivextro (tedizolid-phosphate) Revenues 2013 – 2019 (US$ Millions) 23

FIG. 10 Global Anti-Bacterial Drugs Market – Zerbaxa (ceftolozane + tazobactam) Revenues 2013 – 2019 (US$ Millions) 24

FIG. 11 Global Anti-Bacterial Drugs Market – Avycaz (ceftazidime-avibactam) Revenues 2013 – 2019 (US$ Millions) 25

FIG. 12 Global Anti-Bacterial Drugs Market – Zyvox (linezolid) Revenues 2013 – 2019 (US$ Millions) 26

FIG. 13 Global Anti-Bacterial Drugs Market – Avelox (moxifloxacin) Revenues 2013 – 2019 (US$ Millions) 27

FIG. 14 Global Anti-Bacterial Drugs Market – Augmentin (amoxicillin + clavulanic acid) Revenues 2013 – 2019 (US$ Millions) 28

FIG. 15 Global Anti-Bacterial Drugs Market – Zosyn/Tazocin (piperacillin + tazobactam) Revenues 2013 – 2019 (US$ Millions) 29

FIG. 16 Global Anti-Bacterial Drugs Market – Invanz (ertapenem) Revenues 2013 – 2019 (US$ Millions) 30

FIG. 17 Global Anti-Bacterial Drugs Market – Tygacil (tigecyline) Revenues 2013 – 2019 (US$ Millions) 31

FIG. 18 Global Anti-Bacterial Drugs Market – Other Anti-Bacterial Drug Revenues 2013 – 2019 (US$ Millions) 32

FIG. 19 Global Anti-Bacterial Drugs Market – Surotomycin Revenues 2013 – 2019 (US$ Millions) 33

FIG. 20 Global Anti-Bacterial Drugs Market – Solitaire (solithromycin) Revenues 2013 – 2019 (US$ Millions) 34

FIG. 21 Global Anti-Bacterial Drugs Market – Delafloxacin Revenues 2013 – 2019 (US$ Millions) 35


7

FIG. 22 Global Anti-Bacterial Drugs Market – Plazomycin Revenues 2013 – 2019 (US$ Millions) 36

FIG. 23 Global Anti-Bacterial Drugs Market – Taksta Revenues 2013 – 2019 (US$ Millions) 36

FIG. 24 Global Anti-Bacterial Drugs Market – Cadazolid Revenues 2013 – 2019 (US$ Millions) 37

FIG. 25 Global Anti-Bacterial Drugs Market – Carbavance Revenues 2013 – 2019 (US$ Millions) 38

FIG. 26 Global Anti-Bacterial Drugs Market – Eravacycline Revenues 2013 – 2019 (US$ Millions) 39

FIG. 27 North America Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions) 43

FIG. 28 Europe Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions) 44

FIG. 29 Asia-Pacific Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions) 46

FIG. 30 Latin-America Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions) 47

FIG. 31 Middle-East Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions) 48

FIG. 32 Africa Anti-Bacterial Drugs Market Revenues 2013 – 2019 (US$ Millions) 49

FIG. 33 Key Players Market Share: Global Anti-Bacterial Drugs Market, 2014 (%) 50


8

List of Tables

TABLE 1 List of companies covered in this report 13

TABLE 2 Global Anti-Bacterial Drugs Market, by Geography, 2013 - 2019 (US$ Mn) (CAGR: 2015 - 2019) 42


9

Chapter 1 Preface

1.1 Research Scope

Chapter Number Segment Description

Chapter 1:

Preface

Research Scope

The preface provides a brief overview of the flow of the

research report. The overview is further supplemented by a

graphical representation of the segments analyzed in the

report. This is followed by the postulations or assumptions

considered for analysis of different segments.

Research Methodology Provides the methodology adopted by SA-BRC while

estimating the current and future market in terms of value.

Chapter 2:

Précis Inferences & Summary

The chapter lists down key (quantitative and qualitative)

highlights and takeaways of the market as reported in the

study.

Chapter 3:

Market Dynamics

Drivers, Inhibitors &

Opportunities

Explains the foremost factors that are affecting the growth

(positively and negatively) of the Anti-Bacterial Drugs

Market.

Chapter 4:

Current Drugs Market

Size & Forecast –

Anti-Bacterial Drugs

Market Estimations for

Current Marketed Anti-

Bacterial Drugs

Drugs analyzed in this segment include Cubicin,

Teflaro/Zinforo, Dificid, Dalvance, Orbactiv, Sivextro,

Zerbaxa, Avycaz, Zyvox, Avelox, Augmentin,

Zosyn/Tazocin, Invanz and Tygacil. Estimates market value

with 2013 & 2014 as historical years and forecast of 2015-

2019.

Chapter 5:

Pipeline Drugs

Market Size &

Forecast – Anti-

Bacterial Drugs

Market Estimations for Anti-

Bacterial Drugs in Pipeline

Drugs analyzed in this segment include Surotomycin,

Solithromycin, Delafloxacin, Plazomycin, Taksta, Cadazolid,

Carbavance, Eravacycline and Others. Estimates market

value with forecast between 2015 and 2019 based on

estimated approval dates.

Chapter 6:

Geography Market

Size & Forecast –

Anti-Bacterial Drugs

Demographical Analysis

Provides estimates by value for 6 geographies of North

America, Europe, Asia-Pacific, Latin America, Middle-East

and Africa. Estimates with 2013 & 2014 as historical years

and forecast of 2015-2019.

Chapter 7:

Key Player Analysis

Recent Developments &

Competitive Strategies

Elaborates the market share of key players (2014), recent

developments for the years 2013, 2014 & 2015 and major

competitive strategies adopted by companies in this area

based on events for past 2 years.


10

Chapter 8:

Epilogue

Postscript qualitative

Overview

Provides postscript content to the report and includes an

informal perspective on the market with the best possible

outcome by the end of forecast period.

Companies Covered: Qualitative and Quantitative

Analysis

Merck & Co, Cubist Pharmaceuticals, Astrazeneca, Forest

Laboratories, Johnson & Johnson (Janssen Pharma), Mpex

Pharmaceuticals, Targanta Therapeutics, Nektar

Therapeutics, Paratek Pharmaceuticals, Pfizer, Cempra

Pharmaceuticals, Actavis Pharmaceuticals, Optimer

Pharmaceuticals, GlaxoSmithKline (GSK), Takeda , Durata

Therapeutics, Melinta, The Medicines Company, etc.

1.1.1 Market Segmentation

FIG. 1 Market Segmentation: Anti-Bacterial Drugs Market Assessment & Forecast (2015-2019)

Source: SA-BRC Analysis

Antibacterial Drugs Market

Current Drugs Geography

Europe

Latin America

Asia-Pacific

North

AmericaSurotomycinCubicin

Teflaro/Zinforo

Pipeline Drugs

Dificid

Dalvance

Orbactiv

Sivextro

Zerbaxa

Avycaz

Zyvox

Avelox

Augmentin

Zocyn/Tazocin

Solithromycin

Delafoxacin

Plazomycin

Taksta

Cadazolid

Carbavance

Eravacycline

Middle-East

Africa

Invanz

Tygacil


12

1.2 Methodology of Research

FIG. 2 Research Methodology: Global Anti-Bacterial Drugs Market Assessment

Source: SA-BRC Analysis. **Websites mentioned in the above representation are few examples from our exhaustive list of references that

cannot be compiled in entirety

Quantitative

Research

Qualitative

Research

Primary Research Secondary/Desk Research

Online-web (CATI/CAWI/CAPI)

Telephonic and video conference

Interviewee Location: Multiple

respondents from each of 6 geographies

Interviewee Field Exp.: All Interviewees

were c-level, d-level, VP level and senior

management

Target Information: validation of

secondary findings; cross-verification of

other primary interviews,

Organization – Research Institutes,

Manufacturers, Distributors, Resellers

Proprietary third party databases

In-house data repository

Company websites

Annual Reports/ SEC Filings

Investor presentations

Equity & Stock

(Seeking Alpha, Zacks, Medical Buyer,

Fierce Pharma, Market Watch, Wall

Street Journal, etc.)

Primary Research Secondary/Desk Research

Scientist blogs

Online communities/Scientist Forums

Online chat with KOLs/experts

Focused Group Discussions

Target Information: Insights on market

trends, market impact factors, marketing

and awareness programs etc.

Unicef.org, CDC, WHO, NHS, NIH

Nature.com, ipwatchdog.com,

Accessdata, U.S. FDA, Bloomberg

USPTO.gov, espacenet.com

IMS Health

Bloomberg

Cegedim

Company websites and investor

presentations.

Data triangulation was done for the information (quantitative/qualitative) collected through

primary and secondary sources. Analysis also included evaluation of all major macro and

microeconomic factors.

Post data triangulation process, the summary of our study was shared with KOLs and industry

experts to suggest further insights to our analysis as well as validate the overall Anti-Bacterial

Drugs Market.

Key Findings

Market Forecast

Insight Generation

Spearhead-Acuity Team


13

1.2.1 Companies covered in this report

TABLE 1 List of companies covered in this report

S.No Company Name S.No Company Name

1 Merck & Co 2 Pfizer

3 Cubist Pharmaceuticals 4 Cempra Pharmaceuticals

5 Astrazeneca 6 Actavis Pharmaceuticals

7 Forest Laboratories 8 Optimer Pharmaceuticals

9 Johnson & Johnson (Janssen Pharma) 10 GlaxoSmithKline (GSK)

11 Mpex Pharmaceuticals 12 Takeda

13 Targanta Therapeutics 14 Durata Therapeutics

15 Nektar Therapeutics 16 Melinta

17 Paratek Pharmaceuticals 18 The Medicines Company

Source: Proprietary data sources, KOL opinions, Primary Interviews, SA-BRC Analysis


56

Disclaimer:

SA-BRC Market Research is an informative Market Research Company with the sole intention of

sharing market related insights. The information provided in our research reports or on sa-brc.com

though collected through authentic sources, analyzed and cross validated through Key Opinion

Leaders (KOLs) in the industry; neither the company nor authors provide any kind of warranty about

the content – both qualitative and quantitative.

Contact

John Whitmore

10685-B Hazelhurst Dr. #17411

Houston, TX 77043

United States

Contac Number: +1(832)-426-3701

Email: [email protected], [email protected]

Website: www.sa-brc.com

mailto:[email protected]

mailto:[email protected]

http://www.sa-brc.com/